TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

This study is testing a combination of TACE (a procedure that delivers chemotherapy directly into liver tumors while blocking their blood supply) with an immunotherapy drug called tislelizumab for people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) that has not responded to at least one prior systemic treatment. **You may be eligible if...** - You are 18 or older - You have confirmed unresectable or metastatic intrahepatic bile duct cancer - You have already tried at least one line of systemic treatment (chemotherapy or targeted therapy) that did not work or caused unacceptable side effects - You have at least one measurable tumor - You have adequate blood count, liver, and kidney function - Your overall health allows for treatment (ECOG performance status 0–2) - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have had a stroke, blood clot, or pulmonary embolism within the past 6 months - You have had major surgery, RFA, or resection within the past 4 weeks - You have previously received an anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy drug - You have active autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding - You have active hepatitis B and C co-infection, active tuberculosis, or HIV - You have a history of interstitial lung disease Talk to your doctor to see if this trial is right for you.